Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later
Carolina Digital Repository (University of North Carolina at Chapel Hill) · 06.01.2023
DOI: 10.17615/4bvv-ke89 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 06.01.2023. Verfasst von Caitlin A. Williams und 39 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3 M-052, a synthetic toll-like receptor (TLR) 7/8 agonist, in a squalene emulsion (Protein+3 M-052-SE) was safe and immunogenic in infant rhesus macaques. Here, we demonstrate that broadly neutralizing and spike-binding antibodies against variants of concern (VOC), as well as T cell responses, persisted for 12 months. At one year, corresponding to human toddler age, we challenged vaccinated rhesus macaques and age-matched non-vaccinated controls intranasally and intratracheally with a high-dose of heterologous SARS-CoV-2 B.1.617.2 (Delta). Seven of eight control rhesus macaques exhibited severe interstitial pneumonia and high virus replication in the upper and lower respiratory tract. In contrast, vaccinated rhesus macaques had faster viral clearance with mild to no pneumonia. Neutralizing and binding antibody responses to the B.1.617.2 variant at the day of challenge correlated with lung pathology and reduced virus replication. Overall, the Protein+3 M-052-SE vaccine provided superior protection to the mRNA-LNP vaccine, emphasizing opportunities for optimization of current vaccine platforms. Notably, the observed efficacy of both vaccines one year after vaccination supports the implementation of an early life SARS-CoV-2 vaccine.
Schlagwörter
Zitieren
APA
Williams, C. A., Paris, K. D., Watanabe, J., Corbett, K. S., Lakshmanappa, Y. S., Herbek, S. L., Roh, J. W., Sammak, R. L., Pollard, R. E., Olstad, K. J., Scobey, T., Fouda, G. G., Yee, J. L., Elizaldi, S. R., Dittmer, D. P., Hopkins, L., Cano, P., Cross, K., Carfı́, A., …, & Montefiori, D. C. (2023). Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/4bvv-ke89
Vancouver
Williams CA, Paris KD, Watanabe J, Corbett KS, Lakshmanappa YS, Herbek SL, et al. Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2023. doi:10.17615/4bvv-ke89
BibTeX
@article{Williams2023,
author = {Williams, Caitlin A. and Paris, Kristina De and Watanabe, Jennifer and Corbett, Kizzmekia S. and Lakshmanappa, Yashavanth Shaan and Herbek, Savannah L. and Roh, Jamin W. and Sammak, Rebecca L. and Pollard, Rachel E. and Olstad, Katherine J. and Scobey, Trevor and Fouda, Genevieve G. and Yee, JoAnn L. and Elizaldi, Sonny R. and Dittmer, Dirk P. and Hopkins, Lincoln and Cano, Patricio and Cross, Kaitlyn and Carfı́, Andrea and Graham, Barney S. and Rompay, Koen K. A. Van and Permar, Sallie R. and Reader, J. Rachel and Tomai, Mark A. and Lindesmith, Lisa C. and Mallory, Michael L. and Mielke, Dieter and Fox, Christopher B. and Iyer, Smita Swaminathan and Usachenko, Jodie L. and Baric, Ralph Steven and Munt, Jennifer E. and Edwards, Darin K. and Kozlowski, Pamela A. and Ferrari, Guido and Immareddy, Ramya and Milligan, Emma C. and Shen, Xiaoying and Hudgens, Michael G. and Montefiori, David C.},
title = {Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later},
journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
year = {2023},
doi = {10.17615/4bvv-ke89}
}
EUVIMED